Praxis Precision Medicines to Provide Corporate Update and Report First Quarter 2022 Financial Results on Monday, May 9, 2022
02 mai 2022 16h15 HE
|
Praxis Precision Medicines, Inc.
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Showcases Largest Targeted Epilepsy Portfolio in Industry at 2022 Epilepsy Day
27 avr. 2022 08h25 HE
|
Praxis Precision Medicines, Inc.
BOSTON, April 27, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Host Epilepsy Day on April 27, 2022
13 avr. 2022 08h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Present Data from PRAX-944 for Essential Tremor at 2022 American Academy of Neurology Annual Meeting
01 avr. 2022 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Present at Stifel’s 4th Annual CNS Day
21 mars 2022 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, March 21, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Present at Cowen’s 42nd Annual Healthcare Conference
01 mars 2022 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
28 févr. 2022 06h00 HE
|
Praxis Precision Medicines, Inc.
PRAX-114 Phase 2/3 monotherapy MDD Aria Study topline results expected in June 2022 PRAX-944 Phase 2a ET topline results expected in May 2022; to include open-label and placebo-controlled withdrawal...
Praxis Precision Medicines to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
22 févr. 2022 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Announces Publication of Preclinical Data Highlighting Differentiated and Potent Antiepileptic Activity of PRAX-562
18 janv. 2022 09h00 HE
|
Praxis Precision Medicines, Inc.
PRAX-562 demonstrated robust preclinical antiseizure activity and exhibited an improved preclinical tolerability profile compared to standard-of-care Praxis expects to initiate a Phase 2 trial in the...
Praxis Precision Medicines to Host Movement Disorder Day on December 17, 2021
10 déc. 2021 11h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...